2026 Q1 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 19 min
1,595 GBP/osake
Viimeisin osinko
1,73%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 72 | - | - | ||
| 46 | - | - | ||
| 27 | - | - | ||
| 73 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 10.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenToday we have thus reached the previous pivot bottom at 1692.50kr! The two next support levels will be at the MA200-line (approx 1647kr) and a previous pivot bottom from January (1622.50kr). Negative bearish engulfing today (can in itself be ignored during ongoing decline) does not yet give a signal for an upturn. Robot trading is steady and apparently set for lower kuirser. VWAP 1713kr can be dampening in the decline. MA200 next support?? Larger institutions now need to become interested in the stock for there to be a sustained upturn again...
·1 päivä sittenThe US drug agency FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies. "For 60 years, we have conducted clinical trials in the same way, where important data signals can take years to reach the FDA. The delay can unnecessarily postpone regulatory decisions and slow down the drug development timeline," says FDA Commissioner Marty Makary. The initiative means that data is automatically retrieved from patient records and shared in real-time with both the FDA and pharmaceutical companies, instead of manual processes. The pilot program is expected to include five to nine companies and is based on initial studies from Astra Zeneca and Amgen in cancer treatment, supported by technology from Paradigm Health. According to the FDA, the model can improve safety monitoring, shorten development times, and make clinical studies more accessible. The technology can also help companies make faster decisions about continuing or discontinuing projects.·1 päivä sittenThe outcome shows that revenue, adjusted EBIT and adjusted earnings per share were all 2 percent above the company's consensus. The bank notes that the company's most important brands managed to counteract the effect of VBP (Volume-Based Procurement), a Chinese government policy that forces significant price reductions on medicines in exchange for guaranteed sales in large volumes to public hospitals. Furthermore, the latest positive clinical results for tozorakimab were a positive surprise, according to Bank of America. "Questions during the earnings call may focus on the company's application and launch strategy for the asset," the bank writes. Bank of America adds that focus may also be directed towards the upcoming results (11 expected), especially for camizestrant, given that competing applications for giredestrant may come into focus and how the company might aim to position itself competitively. Bank of America reiterates its buy recommendation with a target price of 16 500 British pence, which implies an upside potential of 18,7 percent.
·1 päivä sittenConference call at 12 hopefully can trigger the share price a little.
·1 päivä sittenI find it difficult to explain the logic behind today's price movement..·1 päivä sittenAnd positive news for the industry keeps coming: "The US Food and Drug Administration FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies." There are probably few pharmaceutical companies that have so much in the pipeline as Astra Zeneca. A faster path to market would have meant many billions in reduced cost and also faster revenues. The market doesn't even react. Is it stupid?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 19 min
1,595 GBP/osake
Viimeisin osinko
1,73%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenToday we have thus reached the previous pivot bottom at 1692.50kr! The two next support levels will be at the MA200-line (approx 1647kr) and a previous pivot bottom from January (1622.50kr). Negative bearish engulfing today (can in itself be ignored during ongoing decline) does not yet give a signal for an upturn. Robot trading is steady and apparently set for lower kuirser. VWAP 1713kr can be dampening in the decline. MA200 next support?? Larger institutions now need to become interested in the stock for there to be a sustained upturn again...
- ·1 päivä sittenThe US drug agency FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies. "For 60 years, we have conducted clinical trials in the same way, where important data signals can take years to reach the FDA. The delay can unnecessarily postpone regulatory decisions and slow down the drug development timeline," says FDA Commissioner Marty Makary. The initiative means that data is automatically retrieved from patient records and shared in real-time with both the FDA and pharmaceutical companies, instead of manual processes. The pilot program is expected to include five to nine companies and is based on initial studies from Astra Zeneca and Amgen in cancer treatment, supported by technology from Paradigm Health. According to the FDA, the model can improve safety monitoring, shorten development times, and make clinical studies more accessible. The technology can also help companies make faster decisions about continuing or discontinuing projects.·1 päivä sittenThe outcome shows that revenue, adjusted EBIT and adjusted earnings per share were all 2 percent above the company's consensus. The bank notes that the company's most important brands managed to counteract the effect of VBP (Volume-Based Procurement), a Chinese government policy that forces significant price reductions on medicines in exchange for guaranteed sales in large volumes to public hospitals. Furthermore, the latest positive clinical results for tozorakimab were a positive surprise, according to Bank of America. "Questions during the earnings call may focus on the company's application and launch strategy for the asset," the bank writes. Bank of America adds that focus may also be directed towards the upcoming results (11 expected), especially for camizestrant, given that competing applications for giredestrant may come into focus and how the company might aim to position itself competitively. Bank of America reiterates its buy recommendation with a target price of 16 500 British pence, which implies an upside potential of 18,7 percent.
- ·1 päivä sittenConference call at 12 hopefully can trigger the share price a little.
- ·1 päivä sittenI find it difficult to explain the logic behind today's price movement..·1 päivä sittenAnd positive news for the industry keeps coming: "The US Food and Drug Administration FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies." There are probably few pharmaceutical companies that have so much in the pipeline as Astra Zeneca. A faster path to market would have meant many billions in reduced cost and also faster revenues. The market doesn't even react. Is it stupid?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 72 | - | - | ||
| 46 | - | - | ||
| 27 | - | - | ||
| 73 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 10.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 19 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 10.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
1,595 GBP/osake
Viimeisin osinko
1,73%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenToday we have thus reached the previous pivot bottom at 1692.50kr! The two next support levels will be at the MA200-line (approx 1647kr) and a previous pivot bottom from January (1622.50kr). Negative bearish engulfing today (can in itself be ignored during ongoing decline) does not yet give a signal for an upturn. Robot trading is steady and apparently set for lower kuirser. VWAP 1713kr can be dampening in the decline. MA200 next support?? Larger institutions now need to become interested in the stock for there to be a sustained upturn again...
- ·1 päivä sittenThe US drug agency FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies. "For 60 years, we have conducted clinical trials in the same way, where important data signals can take years to reach the FDA. The delay can unnecessarily postpone regulatory decisions and slow down the drug development timeline," says FDA Commissioner Marty Makary. The initiative means that data is automatically retrieved from patient records and shared in real-time with both the FDA and pharmaceutical companies, instead of manual processes. The pilot program is expected to include five to nine companies and is based on initial studies from Astra Zeneca and Amgen in cancer treatment, supported by technology from Paradigm Health. According to the FDA, the model can improve safety monitoring, shorten development times, and make clinical studies more accessible. The technology can also help companies make faster decisions about continuing or discontinuing projects.·1 päivä sittenThe outcome shows that revenue, adjusted EBIT and adjusted earnings per share were all 2 percent above the company's consensus. The bank notes that the company's most important brands managed to counteract the effect of VBP (Volume-Based Procurement), a Chinese government policy that forces significant price reductions on medicines in exchange for guaranteed sales in large volumes to public hospitals. Furthermore, the latest positive clinical results for tozorakimab were a positive surprise, according to Bank of America. "Questions during the earnings call may focus on the company's application and launch strategy for the asset," the bank writes. Bank of America adds that focus may also be directed towards the upcoming results (11 expected), especially for camizestrant, given that competing applications for giredestrant may come into focus and how the company might aim to position itself competitively. Bank of America reiterates its buy recommendation with a target price of 16 500 British pence, which implies an upside potential of 18,7 percent.
- ·1 päivä sittenConference call at 12 hopefully can trigger the share price a little.
- ·1 päivä sittenI find it difficult to explain the logic behind today's price movement..·1 päivä sittenAnd positive news for the industry keeps coming: "The US Food and Drug Administration FDA is launching pilot studies for real-time clinical trials and plans a broader program where AI is used to streamline data collection. The goal is to accelerate drug development by giving the agency direct access to data during the course of the studies." There are probably few pharmaceutical companies that have so much in the pipeline as Astra Zeneca. A faster path to market would have meant many billions in reduced cost and also faster revenues. The market doesn't even react. Is it stupid?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 72 | - | - | ||
| 46 | - | - | ||
| 27 | - | - | ||
| 73 | - | - |
Välittäjätilasto
Dataa ei löytynyt